Western Connecticut Health Network, Health Quest combine to form $2.4B system

FierceHealthcare | April 04, 2019

Danbury-based Western Connecticut Health Network and New York-based Health Quest announced Wednesday they have merged to create a $2.4 billion system called Nuvance Health. The announcement came the same day regulators approved a certificate of need application to transfer ownership of both health systems into a single, newly formed not-for-profit entity. The name Nuvance was derived from a combination of "new" and "advance," officials said. The combined system will care for patients across New York's Hudson Valley and western Connecticut, officials said.  The merger comes a little more than a year after the two systems formally agreed to create a new system.

Spotlight

Study objective to determine the effect of elafibranor, a dual PPAR alpha/delta agonist, on fatty acid saturationPhase 2 study to evaluate the effect of a 6-week, once daily treatment of elafibranor (120mg) vs. placebo on hepatic lipid composition in patients with Nonalcoholic Fatty Liver (NAFL)State of the art non invasive techniques (H-MRS) to be used to provide indications on both quantitative and qualitative evolution of liver fat


Other News
HEALTH TECHNOLOGY

Alcon Strengthens Leadership in IOL Innovation with Launch of Clareon Portfolio in the U.S.

Alcon | March 07, 2022

Alcon the global leader in eye care dedicated to helping people see brilliantly, announced the launch of the Clareon®family of intraocular lenses (IOLs) in the U.S. Utilizing Alcon’s most advanced IOL material, Clareon can deliver consistent visual outcomes and exceptional clarity that lasts.°,1-7The Clareon clarity is born out of a glistening-free§IOL material that has among the lowest levels of haze and subsurface nanoglistenings compared to leading competitor IOLs.†,*,1-3 “We are proud to offer our latest IOL technology in the U.S. and other countries across the globe. At Alcon, we are consistently pushing the boundaries to deliver transformational innovation to cataract surgeons and their patients. Clareon is the result of robust R&D efforts at every level—inventive material science, advanced manufacturing techniques and novel delivery systems—to deliver exceptional, long-lasting clarity.” Ian Bell, President, Global Business & Innovation, Alcon The Clareon portfolio leverages many of the same design characteristics and optics as Alcon’s leading IOLs to help deliver the outcomes surgeons expect.8,9Clareon offers sharp, crisp vision with a proprietary edge designed to help reduce glare and posterior capsular opacification.7The lens’ unique and proven STABLEFORCE®Haptics provide superior axial and rotational stability.*,β,8-14Clareon has been extensively researched, with inclusion in 30 published studies worldwide. Clareon Monofocal and Clareon Toric IOLs have already been implanted in more than one million eyes across more than 70 countries.15 Clareon IOLs are inserted using the next-generation, reusable Clareon Monarch®IVDelivery System, which provides precise and controlled implantation and that was designed specifically for the new Clareon material.15,16Clareon Monofocal is also available in the next-generation automated, single-use delivery system, AutonoMe™. “As one of the investigators for the Clareon pivotal trial, I was immediately impressed with the clarity of the new IOL material, delivery system and the consistent refractive outcomes,” said Dr. Samuel H. Lee, MD, Ophthalmologist, Sacramento, CA.** “Today, the clarity of Clareon persists four years later in my trial patients, with the optic performance that I expect from Alcon IOLs, as well as continued high patient satisfaction.” Clareon Monofocal, Clareon PanOptix®, Clareon PanOptix Toric, Clareon Vivity®and Clareon Vivity Toric IOLs are now available in the U.S. Clareon PanOptix offers patients the possibility of 20/20 vision at distance (far), intermediate (at arm’s length) and near (up close), with continuous vision of 20/25 or better.¥,14,17Clareon Vivity is a non-diffractive extended depth of focus lens with wavefront-shaping X-WAVE™ technology, delivering monofocal-quality distance with excellent intermediate and functional near vision and with a monofocal visual disturbance profile.13,18 Clareon Toric will be available in the U.S. later this year. Alcon will be rolling out the Clareon family of IOLs in international markets throughout 2022 and 2023. There are more than 28 million cataract surgeries performed each year in the world. With the aging population and increased life expectancies, these surgeries are expected to increase 3-4% per year for the next 30 years, leading to an estimated 60 million global cataract surgeries annually by 2045.19 About Cataracts A cataract is a cloudy area in the natural lens of the eye that affects vision. As a cataract develops, the eye's lens gradually becomes hard and cloudy, allowing less light to pass through, which makes it more difficult to see. The vast majority of cataracts result from normal aging, but radiation exposure, taking steroids, diabetes and eye trauma can accelerate their development. Cataracts are the most common age-related eye condition and the leading cause of preventable blindness.20Cataracts are treated by removing the eye's cloudy natural lens and surgically replacing it with an IOL. More than 92% of cataract surgeries are considered successful, and patients typically can return to their normal routines within 24 hours.21 About Clareon IOLs and Delivery Systems The family of Clareon intraocular lenses (IOLs) includes the Clareon Aspheric Hydrophobic Acrylic and Clareon Aspheric Toric IOLs, the Clareon PanOptix Trifocal Hydrophobic IOL, Clareon PanOptix Toric, Clareon Vivity Extended Vision Hydrophobic Posterior Chamber IOL and Clareon Vivity Toric IOLs. Each of these IOLs is indicated for visual correction of aphakia in adult patients following cataract surgery. In addition, the Clareon Toric IOLs are indicated to correct pre-existing corneal astigmatism at the time of cataract surgery. The Clareon PanOptix lens mitigates the effects of presbyopia by providing improved intermediate and near visual acuity while maintaining comparable distance visual acuity with a reduced need for eyeglasses, compared to a monofocal IOL. The Clareon Vivity lens mitigates the effects of presbyopia by providing an extended depth of focus. Compared to an aspheric monofocal IOL, the lens provides improved intermediate and near visual acuity while maintaining comparable distance visual acuity. All of these IOLs are intended for placement in the capsular bag. Careful preoperative evaluation and sound clinical judgment should be used by the surgeon to decide the risk/benefit ratio before implanting any IOL in a patient with any of the conditions described in the Directions for Use that accompany each IOL. Prior to surgery, physicians should provide prospective patients with a copy of the Patient Information Brochure available from Alcon, informing them of possible risks and benefits associated with these IOLs. Reference the Directions for Use labelling for each IOL for a complete listing of indications, warnings and precautions. About Alcon Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 24,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care.

Read More

FUTURE OF HEALTHCARE

Virtua Health and Medtronic Share Plans to Reimagine Traditional Health Care Models

Virtua Health | December 16, 2021

Virtua Health and Medtronic plc announce a five-year partnership focused on improving delivery of quality care for residents of South Jersey, particularly those who reside in underserved communities or face systemic barriers to care. Medtronic LABS, an independent impact-focused organization funded by Medtronic plc, will simultaneously launch a separate pilot collaboration with the Cherry Hill Free Clinic and Virtua to address care and food access for people with chronic conditions – the first U.S.-based initiative for Medtronic LABS. "I truly believe technology is the path forward to improving human welfare," said Geoff Martha, Chairman and CEO of Medtronic. "This new partnership and collaboration demonstrate the opportunity to use technology to tackle health challenges in a localized, grassroots way. By taking a data-informed approach, we can help improve access and outcomes for patients with chronic conditions in southern New Jersey." "This partnership presents a significant opportunity to accelerate health equity and better outcomes for individuals and families in our community. Together, we will apply the latest research and innovation to the fundamentals of community-based care, allowing us to identify and empower those who need support to achieve the best-possible quality of life." Dennis W. Pullin, FACHE, president and CEO of Virtua Health The scope of the partnership includes the following projects and will expand over time. Heart Health: Medtronic plc and Virtua Health will develop a program to optimize care for hospital patients diagnosed with heart failure, with a focus on slowing the progression of the disease and enhancing the experience of both patient and provider. By employing Medtronic's data-driven, decision-support tools, Virtua clinicians will provide ongoing resources post-hospitalization, minimizing the likelihood of readmission and creating sustainable, enriching solutions for the individual. Outpatient Care Continuity: The partnership will also optimize patient care in high-value outpatient settings, including ambulatory surgery centers. Additionally, Medtronic plc and Virtua will expand Virtua's hospital at home program, which is due to launch officially in early 2022 and aims to reduce the resource-strain on the health system while allowing eligible patients to heal from the comfort of home. Medtronic LABS' collaboration intends to address population health in the following ways: Community Health and the Cherry Hill Free Clinic: Community health workers and clinicians at the Cherry Hill Free Clinic will utilize Medtronic LABS' digital health platform, extending their reach through mobile tools and point-of-care diagnostics. Those identified as having (or being at risk for) chronic illnesses, such as Type 2 diabetes or hypertension, will then connect to the Cherry Hill Free Clinic for follow-up care. Over time, the platform will become more sophisticated and specific as the data accumulates and reveals localized trends and challenges. Food Access: Medtronic LABS will also support Virtua's Eat Well food access programs, specifically the Food Farmacies located inside Virtua Mount Holly Hospital and the Virtua Health & Wellness Center – Camden. Medtronic LABS and Virtua will identify those at risk for food insecurity – due to financial circumstances or limited health literacy – and connect them to free food, nutrition education, and social-work services. "I am honored that Medtronic LABS and Virtua recognize the essential services we provide at the Cherry Hill Free Clinic, and that they are combining their resources and expertise toward enhancing continuity of care for existing and prospective patients," said Jubril Oyeyemi, MD, founder and chief medical officer of the Cherry Hill Free Clinic. "The CDC estimates that 20 percent of Camden County residents do not have health insurance. By creating pathways to care, we build healthier communities." "Medtronic LABS has trained more than 2,000 health workers and provided screenings to more than a million people worldwide. To date, we have focused our efforts on communities in Kenya, Ghana, India, and the Philippines, which is why we are thrilled to partner with Virtua Health on our first U.S.-based endeavor," said Ruchika Singhal, vice president of Medtronic LABS. "In time, this collaboration will create scalable, replicable improvements to the care-delivery model while advancing health and wellness on an individual level." About the Partners Medtronic: Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. Medtronic LABS is an independent, non-profit structure with multiple entities including an operating foundation, a social business, an in-country non-profit, and for-profit subsidiaries. Medtronic LABS is setting out to design the health system of the future: one that is equitable, tech-enabled, and patient-centered. To date, Medtronic LABS has screened more than 1M patients and improved clinical outcomes for over 35K patients in Kenya, Ghana, India, and the Philippines. Virtua Health is an integrated health care system and the trusted partner for personalized health care and wellness for communities in southern New Jersey. With more than 280 locations and 14,000 colleagues, Virtua provides high-quality care with more than two million annual encounters across the full range of community and tertiary health services – from preventive care to urgent care through specialty services in cancer, women's health, neuroscience, and orthopedics to complex minimally invasive cardiac surgery and organ transplantation. Performing more than 175,000 surgeries at its hospitals and network of ambulatory centers, Virtua is one of the largest providers of surgery in the state. As a not-for-profit leader, Virtua continues to improve social determinants in health and has distributed more than 160,000 pounds of fresh produce in underserved areas to address food insecurity. Virtua is advancing important partnerships into the future to help you be well, get well, and stay well. Cherry Hill Free Clinic (CHFC) is an independent 501(c)(3) with the mission of providing free primary care to the uninsured and under-insured. CHFC is supported by Virtua Health, which provides lab, radiology and, in some cases, specialty care to CHFC patients.

Read More

FUTURE OF HEALTHCARE

Modivcare Announces Acquisition of Guardian Medical Monitoring

Modivcare Inc. | May 19, 2022

Modivcare Inc. a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions focused on improving patient outcomes, announced the Company’s Remote Patient Monitoring Segment has acquired Guardian Medical Monitoring, LLC from its parent company, Guardian Alarm. Guardian Medical Monitoring is a leading provider of remote patient monitoring solutions to Managed Care Organizations and state Medicaid payors including Personal Emergency Response Systems and medication management. GMM’s RPM platform currently monitors approximately 50,000 aging and chronically ill patients on behalf of their respective payors. “Remote patient monitoring is essential to Modivcare’s mission to connect patients to care through our integrated supportive care platform. Our comprehensive remote patient monitoring offering allows patients to safely age in their homes with technology-enabled connectivity to care which increases patient engagement and reduces costs. We are excited to accelerate the growth of Modivcare’s RPM Segment with the acquisition of GMM, and we are excited to welcome the GMM team to Modivcare.” Daniel E. Greenleaf, Modivcare’s President and Chief Executive Officer Jason Anderson, President, Modivcare Home added, “Guardian Medical Monitoring is a complementary acquisition for Modivcare’s RPM Segment, strengthening our customer relationships and expanding our service footprint across key states. Additionally, this acquisition provides an opportunity to expand our E3 engagement platform across a larger base of members and payors. Modivcare’s E3 platform helps our partners reduce gaps in care and address social determinants of health by engaging, educating, and empowering members using our proprietary platform.” About Modivcare Modivcare Inc. is a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions for public and private payors and their patients. Our value-based solutions address the social determinants of health (SDoH), enable greater access to care, reduce costs, and improve outcomes. We are a leading provider of non-emergency medical transportation, personal care and remote patient monitoring.

Read More

FUTURE OF HEALTHCARE

Omega Healthcare Acquires Reventics, a Physician Focused CDI and RCM Company

Omega Healthcare | March 09, 2022

Omega Healthcare, a leading healthcare management solutions partner supporting the broad healthcare ecosystem, today announced its acquisition of Reventics, aDenver, CObased company. Reventics is a clinical documentation improvement ("CDI") and revenue cycle management ("RCM") solutions provider that delivers Provider Engagement Solutions to enhance physician reimbursement and compliance, while improving clinical quality measures. This acquisition enables Omega Healthcare to expand its core coding and RCM offering by leveraging Reventics' proprietary cloud native platforms for CDI and RCM - RevCDI and RevMAX - along with expert clinical resources to drive improved outcomes for its clients. The transaction is part of Omega Healthcare's strategic growth plan to expand its existing CDI capabilities through technology-driven solutions, giving Omega exceptional scale and proficiency in this specialized competency. "Reventics brings to our organization clinical excellence, analytic capabilities, and new age technologies to complement Omega's existing technology and automation services. Not only is this a strategic fit that will benefit our clients, but we will be able to expand our CDI and RCM capabilities through this acquisition, while increasing our AI capabilities as well." Anurag Mehta, CEO of Omega Healthcare "We see our core values of "client first" approach reflected in Omega's own philosophy and are excited by how our clients could benefit from the larger enterprise and its extensive capabilities. We believe the client partnerships we currently enjoy will only be strengthened through this transaction." saysArnab Sen, CEO of Reventics. " "Omega is excited to welcome the Reventics team and is eagerly looking forward to creating enhanced value for its customers under the combined leadership" addedSumithra Gomatam, Executive Chair of Omega. Anurag Mehtawill continue to serve as the CEO of the combined entity. About Omega Healthcare Founded in 2003, Omega helps payers, providers, and pharmaceutical companies eliminate administrative burdens, accelerate cash flow, and reduce health management costs while enhancing patient care. The company streamlines medical billing, coding, and collections processes and provides virtual nursing services, including triage, care continuation, clinical documentation improvement, and re-admittance avoidance. Combining the largest medical coding staff in the world with proprietary technology, analytics, and automation capabilities, Omega provides the most comprehensive outsourced solutions in the industry and is ranked among the top revenue cycle management business process services by industry analysts. Backed by the Private Equity business within Goldman Sachs Asset Management and Everstone Group, Omega has more than 20,000 employees acrossthe United States,India,the Philippines. About Reventics Reventics is a physician-focusedclinical documentation improvement (CDI)andrevenue cycle management (RCM)company. The company is changing the way the industry thinks about CDI and RCM by placing the provider at the center of its solutions. From the AI that powers Reventics' products to its physician-led delivery approach, Reventics drives an unrelenting focus on clinicians, to improve their operational and financial outcomes. Reventics' approach is based on using itsto deliver Provider Engagement Solutions that enhance physician reimbursement and compliance while improving clinical quality measures.

Read More

Spotlight

Study objective to determine the effect of elafibranor, a dual PPAR alpha/delta agonist, on fatty acid saturationPhase 2 study to evaluate the effect of a 6-week, once daily treatment of elafibranor (120mg) vs. placebo on hepatic lipid composition in patients with Nonalcoholic Fatty Liver (NAFL)State of the art non invasive techniques (H-MRS) to be used to provide indications on both quantitative and qualitative evolution of liver fat

Resources